Abstract: The formation of scars at a wound site is reduced by contacting the wound site with an effective dose of an inhibitor of focal adhesion kinase (FAK) formulated in a pullulan hydrogel The release profile of the FAK inhibitor can be adjusted according to the nature of the wound, e.g., excisional wounds, burn wounds, etc.

Abstract: Embodiment provided herein are directed to microneedle patches for agent application on a mammal skin. The microneedle patch may comprise a patch scaffold having a surface, and a plurality of microneedles disposed on the surface. Each of the microneedles may be capable of piercing the skin 50 ?m to 1000 ?m deep, and comprises a composite material comprising polyvinylpyrrolidone (PVP) and one or more additional copolymers selected from the group consisting of maltose, leucine, and dileucine.

Abstract: Embodiment provided herein are directed to microneedle patches for agent application on a mammal skin. The microneedle patch may comprise a patch scaffold having a surface, and a plurality of microneedles disposed on the surface. Each of the microneedles may be capable of piercing the skin 50 ?m to 1000 ?m deep, and comprises a composite material comprising polyvinylpyrrolidone (PVP) and one or more additional copolymers selected from the group consisting of maltose, leucine, and dileucine.

Abstract: Disclosed herein are methods and drug compositions for treating Lyme disease and post-treatment Lyme disease syndrome (PTLDS) or chronic Lyme disease (CLD). In one embodiment, a method of treating a subject with Lyme disease involves administering an effective amount of a therapeutic agent selected from the group consisting of tetraethylthiuram disulfide, doxorubicin, epirubicin, azlocillin, cephalothin, josamycin, cefotaxime, cefazolin, erythromycin, calcimycin, gramicidin, cefdinir, gambogic acid, ceftazidime, ticarcillin, valinomycin, moxifloxacin, linezolid, idarubicin, tosufloxacin, loratadine, ceftriaxone, and combinations thereof, and pharmaceutical salts, hydrates, and solvates thereof.

Abstract: Improved electrochemical impedance spectroscopy assays are provided by electrodepositing metallic nanoparticles onto the working electrode for electrochemical impedance spectroscopy. The metallic nanoparticles provide improved assay sensitivity. Electrodeposition of the metallic nanoparticles firmly affixes them to the working electrode, thereby making it easier to clean the working electrode from one assay to the next assay without undesirably removing the metallic nanoparticles.

Abstract: Disclosed herein are methods and drug compositions for treating Lyme disease and post-treatment Lyme disease syndrome (PTLDS) or chronic Lyme disease (CLD). In one embodiment, a method of treating a subject with Lyme disease involves administering an effective amount of a therapeutic agent selected from the group consisting of tetraethylthiuram disulfide, doxorubicin, epirubicin, azlocillin, cephalothin, josamycin, cefotaxime, cefazolin, erythromycin, calcimycin, gramicidin, cefdinir, gambogic acid, ceftazidime, ticarcillin, valinomycin, moxifloxacin, linezolid, idarubicin, tosufloxacin, loratadine, ceftriaxone, and combinations thereof, and pharmaceutical salts, hydrates, and solvates thereof.

Abstract: The present disclosure provides methods and apparatuses for treating tissue ulcers. The apparatuses include elafin protein incorporated into a biocompatible matrix that allows controlled release of the elafin protein to the wound. The biocompatible matrix may be made of biological polymers such as collagen.

Abstract: The present disclosure provides compositions and methods for preventing and treating dyskinesia, such as drug-induced dyskinesia in patients of Parkinson's disease. The compositions, preferably in a sustained release formulation, include L-DOPA, carbidopa, and ranitidine wherein the weight ratio of L-DOPA to carbidopa is in the range of about 1:(0.2-0.3), or include L-DOPA, benserazide, and ranitidine, wherein the weight ratio of L-DOPA to benserazide is in the range of about 1:(0.4-0.6).

Abstract: Embodiment provided herein are directed to microneedle patches for agent application on a mammal skin. The microneedle patch may comprise a patch scaffold having a surface, and a plurality of microneedles disposed on the surface. Each of the microneedles may be capable of piercing the skin 50 ?m to 1000 ?m deep, and comprises a composite material comprising polyvinylpyrrolidone (PVP) and one or more additional copolymers selected from the group consisting of maltose, leucine, and dileucine.

Abstract: Improved electrochemical impedance spectroscopy assays are provided by electrodepositing metallic nanoparticles onto the working electrode for electrochemical impedance spectroscopy. The metallic nanoparticles provide improved assay sensitivity. Electrodeposition of the metallic nanoparticles firmly affixes them to the working electrode, thereby making it easier to clean the working electrode from one assay to the next assay without undesirably removing the metallic nanoparticles.

Abstract: Formulations and methods of use thereof that relate to biocompatible delivery of stabilized porphyrin complexes are provided. Formulations may include microparticles comprising the porphyrin complex, wherein the porphyrin active agent is admixed or coated with a pharmaceutically acceptable stabilizer.